Capture Assays for the Detection of Virus-Specific IgM Antibody

1984 ◽  
pp. 60-71
Author(s):  
Richard S. Tedder
Keyword(s):  
Igm Antibody

Clinical Usefulness of Viral IgM Antibody Test in Sudden Sensorineural Hearing Loss Patient

2011 ◽  
Vol 54 (1) ◽  
pp. 37 ◽  
Author(s):  
Moo Kyun Park ◽  
Jonge Dae Lee ◽  
Byung Don Lee ◽  
Hyun Woo Lim ◽  
Soon Jae Hwang ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Antibody Test ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Clinical Usefulness ◽  
Igm Antibody

A Case of Drug-induced Hypersensitivity Syndrome with Reactivated Human Herpes Virus 6 and Transiently Raised IgM Antibody to Parvovirus B19

2009 ◽  
Vol 71 (6) ◽  
pp. 580-583
Author(s):  
Emiko KAMADA ◽  
Yohei SANO ◽  
Azusa HAYAKAWA ◽  
Yasuko YAMADA ◽  
Yoshihiro IKEDA ◽  
...  
Keyword(s):  
Herpes Virus ◽  
Parvovirus B19 ◽  
Hypersensitivity Syndrome ◽  
Human Herpes ◽  
Drug Induced ◽  
Igm Antibody ◽  
Human Herpes Virus ◽  
Human Herpes Virus 6 ◽  
Herpès Virus

scholarly journals IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jyotsna Shah ◽  
Song Liu ◽  
Hari-Hara Potula ◽  
Prerna Bhargava ◽  
Iris Cruz ◽  
...  
Keyword(s):  
Viral Infections ◽  
Antibody Responses ◽  
Nucleocapsid Proteins ◽  
Igm Antibodies ◽  
Igm Antibody ◽  
Specificity And Sensitivity ◽  
The Us ◽  
Autoimmune Conditions ◽  
Antibody Positivity ◽  
Recombinant Nucleocapsid Protein

Abstract Background Rapid and simple serological assays for characterizing antibody responses are important in the current COVID-19 pandemic caused by SARS-CoV-2. Multiplex immunoblot (IB) assays termed COVID-19 IB assays were developed for detecting IgG and IgM antibodies to SARS-CoV-2 virus proteins in COVID-19 patients. Methods Recombinant nucleocapsid protein and the S1, S2 and receptor binding domain (RBD) of the spike protein of SARS-CoV-2 were used as target antigens in the COVID-19 IBs. Specificity of the IB assay was established with 231 sera from persons with allergy, unrelated viral infections, autoimmune conditions and suspected tick-borne diseases, and 32 goat antisera to human influenza proteins. IgG and IgM COVID-19 IBs assays were performed on 84 sera obtained at different times after a positive RT-qPCR test from 37 COVID-19 patients with mild symptoms. Results Criteria for determining overall IgG and IgM antibody positivity using the four SARS-CoV-2 proteins were developed by optimizing specificity and sensitivity in the COVID-19 IgG and IgM IB assays. The estimated sensitivities and specificities of the COVID-19 IgG and IgM IBs for IgG and IgM antibodies individually or for either IgG or IgM antibodies meet the US recommendations for laboratory serological diagnostic tests. The proportion of IgM-positive sera from the COVID-19 patients following an RT-qPCR positive test was maximal at 83% before 10 days and decreased to 0% after 100 days, while the proportions of IgG-positive sera tended to plateau between days 11 and 65 at 78–100% and fall to 44% after 100 days. Detection of either IgG or IgM antibodies was better than IgG or IgM alone for assessing seroconversion in COVID-19. Both IgG and IgM antibodies detected RBD less frequently than S1, S2 and N proteins. Conclusions The multiplex COVID-19 IB assays offer many advantages for simultaneously evaluating antibody responses to different SARS-CoV-2 proteins in COVID-19 patients.

scholarly journals Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

2021 ◽  
pp. 113046
Author(s):  
A.M. Cook ◽  
S.E. Faustini ◽  
L.J. Williams ◽  
A.F. Cunningham ◽  
M.T. Drayson ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Igm Antibody ◽  
Hospitalised Patients
Sign in / Sign up

Export Citation Format

Share Document